12 week open label, multicenter, non-comparative switch study evaluating efficacy, tolerability and safety of oral ziprasidone in treatment of patients suffering from schizophrenia who have already been treated with another antipsychotic

Trial Profile

12 week open label, multicenter, non-comparative switch study evaluating efficacy, tolerability and safety of oral ziprasidone in treatment of patients suffering from schizophrenia who have already been treated with another antipsychotic

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 29 Aug 2006 Status change
    • 06 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top